Kamau Therapeutics
Kirby Wallace currently serves as the Head of Business Development at Kamau Therapeutics, a position held since July 2023. Prior to this role, Kirby worked as Scientist II at Graphite Bio from May 2021 to May 2023, and as a Scientist at Mammoth Biosciences from July 2020 to April 2021. Kirby's academic journey culminated in a Ph.D. in Biomedical Research - Cancer and Developmental Biology from The University of Tennessee Health Science Center, where significant research contributed to new therapeutic options for high-risk pediatric cancer. Additional experience includes a consulting role at The University of Tennessee Health Science Center, where a competitive analysis was performed, and several positions including a research assistant at EGEN Inc. and an intern at HudsonAlpha Institute for Biotechnology, contributing to impactful biotech research and publications.
This person is not in any teams
This person is not in any offices
Kamau Therapeutics
Kamau Therapeutics is a clinical-stage, next-generation gene correction company harnessing high efficiency targeted gene integration to develop a new class of therapies with the aim to cure a wide range of serious and life-threatening diseases. Our novel gene correction approach, called homology-directed repair (HDR), overcomes prior limitations in specificity, efficiency, and durability of gene editing to offer broad potential for transforming human health outcomes through the delivery of one-time curative cell therapies. Our platform aims treat or cure a range of serious genetic diseases with unmet medical needs.